Is there a generic version of selumetinib available in India?

Since its launch by AstraZeneca in 2020, Selumetinib has quickly attracted attention in the international drug market, especially its unique efficacy in the treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PNs), making it one of the few oral targeted therapies for this rare disease. However, for many patients who need to use this drug, the high price of the original drug has become an unbearable burden. Therefore, whether there are more cost-effective versions of generic drugs, especially Indian versions, has become the focus of public and clinical patients.

Currently, no local pharmaceutical companies, such asCipla, NATCO, Sun Pharma, Dr. Reddy’s, etc., have launched generic versions of selumetinib in the Indian market. This is mainly affected by the following key factors: First, patent protection. Selumetinib is still within the international patent period (some patents extend to 2030). Although India has the world's leading generic drug manufacturing technology, it usually respects international patent regulations and will not develop similar generic products during the patent period unless there is a national public health crisis or compulsory licensing.

The second is market demand. The indications of selumetinib are relatively rare, and it is mainly used in the rare disease population of NF1. Compared with bulk drugs such as imatinib, lenalidomide, ibrutinib, etc., the potential user base of selumetinib is relatively small. This makes many Indian pharmaceutical companies give priority to varieties with short return cycles and high demand when investing in generic development, thus delaying the entry of generic Selumetinib in terms of strategic layout.

In addition, selumetinib, as a complex small molecule targeted drug, involves high technical barriers. Its synthesis route and production process are complicated, and it needs to meet international quality certification standards (such asGMP, WHO PQ, etc.), which also limits the entry of small and medium-sized generic drug companies to a certain extent.

Reference materials:https://www.koselugo.com